GlassScriptPhysician profile
Holly Corley
NPI 1669673331
$9,146.89
in general payments reported to CMS, 2019-2025
52 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $1,119 · 2021: $999 · 2022: $1,217 · 2023: $1,736 · 2024: $1,527 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,865.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,328.53 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,072.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $830.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $745.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $695.70 | 2021-2025 | Ubrelvy, Viberzi, Linzess |
| Amgen INC. | $462.38 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $301.12 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $291.35 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $281.24 | 2020-2025 | Trintellix |
| Shield Therapeutics INC | $276.61 | 2023-2025 | Accrufer |
| Amarin Pharma, INC. | $265.85 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $241.92 | 2022-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.18 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.36 | 2019-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $156.27 | 2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Corley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.